Stock performance and analyst view
- With the advance, BBNX shares were down ~31% YTD; the company went public in its Jan 2025 IPO priced at $17.
- The average rating of 12 analysts is "buy"; median PT $22, per LSEG.
Use of proceeds and recent company updates
- Co intends to use net offering proceeds for general purposes, including for commercialization of Mint, manufacturing facilities expansion, among other uses.
- Early Mon, BBNX said the U.S. FDA cleared Mint and it expects to commercially launch its patch pump in Q1 2027. Also, Senseonics SENS.O announced partnership to integrate its Eversense 365 Continuous Glucose Monitoring system with BBNX's iLet Bionic Pancreas system.
Shares jump after larger-than-expected equity raise
BBNX•
